Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Testicular Cancer Male patients > 18 years of age 2. Patients with histologically proven germ cell neoplasm (gonadal or extragonadal primary) 3. Patients must have the disease not amendable to cure with either surgery or chemotherapy 4. Patients must have failed at least two cisplatin-based combination chemotherapy regimens. 5. Failure on prior regimens will be defined as either A ≥ 25% increase in sum of target lesions, new lesions, or An increasing AFP or HCG above the nadir level. 6. Patients with at least one measurable lesion by CT scan or MRI according to 7. Adequate bone marrow, liver and renal function, assessed no longer than 14 days before treatment start, defined by the following laboratory test limits: WBC > 2.0 x 109/l and platelets > 60 x 109/l, total bilirubin < 2 x upper limit, AST and ALT < 5 x upper limit normal, serum creatinine < 2 x UNL 8. WHO Performance Status 0, 1, 2 9. No concurrent chemotherapy or radiotherapy 10. Life expectancy of at least 12 weeks 11. Absence of any physiological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule 12. A signed informed consent must be obtained prior to any study specific procedures 13. All patients must agree to use adequate contraception during the whole study period  Patients not fulfilling of 2. Primary radiotherapy in the field of target lesion 3. Major surgery (RPLND) within 4 weeks before the start of study drug or concurrent serious non-healing wounds, ulcers or bone fractures. 4. Known serious and active bacterial, viral or fungal infection (> grade II CTC-AE) including HBV, HCV and HIV carrier state. 5. Previous or concurrent malignancy except for basal cell carcinoma of the skin 6. Uncontrolled hypertension. 7. Thrombotic or embolic event in last 6 months prior to inclusion. 8. Impairment of gastrointestinal tract, or GI disease that may influence the bioavailability of oral sorafenib 9. Substance and alcohol abuse (nicotine use is allowed) 10. Known or suspected hypersensitivity to sorafenib. 11. Participants in any other clinical trial using investigational drug within 4 weeks prior to study entry 12. Prior use of investigational or licensed angiogenesis and RAF kinase or MEK inhibitors. 13. Patient unwilling or unable to give informed consent 14. Any condition that may in the investigator's opinion jeopardize the safety of the patient or his compliance in the study